文献速递流行病学与生物统计临床试验与 GCP

孕期无症状细菌性阴道病筛查与治疗的更新证据综述

Screening for Bacterial Vaginosis in Pregnant Adolescents and Women to Prevent Preterm Delivery: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2020-01-01

本综述为美国预防服务工作组(USPSTF)更新证据,纳入44项研究(48篇文献)。未发现评估筛查获益或危害的研究;筛查试验灵敏度0.36–1.0、特异度0.49–1.0。一般产科人群中治疗与37周前分娩无显著关联,既往早产史者证据不一致;治疗相关母体不良事件少见且轻微,宫内暴露危害证据不充分。

要点

  • 未发现直接评估孕期细菌性阴道病筛查获益或危害的研究。
  • 一般产科人群治疗未见37周前分娩显著减少。
  • 既往早产史女性治疗获益证据不一致。

核心结论

  • 筛查试验准确性差异较大,一般产科人群治疗无症状细菌性阴道病未见早产发生率差异,既往早产史女性结论不确定。
  • 治疗相关母体不良事件少见且轻微,但宫内暴露危害的证据不充分。

研究设计与样本

  • 纳入44项研究(48篇文献),包括筛查试验准确性研究、随机临床试验(RCT)、仅评估危害的非随机对照干预研究及甲硝唑或克林霉素的荟萃分析。

主要发现

  • 一般产科人群中,治疗与37周前自然分娩无显著关联(合并绝对危险差-1.44%,95%CI -3.31%至0.43%;8项RCT,n=7571)。
  • 一般产科人群中,治疗与任何37周前分娩无显著关联(合并绝对危险差0.20%,95%CI -1.13%至1.53%;6项RCT,n=6307)。
  • 5项报告既往早产史女性的试验结果不一致,其中3项显示显著获益、2项未显示。
  • 8项RCT显示治疗相关母体不良事件少见且轻微(如念珠菌感染),但活动治疗组略高于安慰剂组。

关键数值与推荐

  • 2项观察性研究荟萃分析:甲硝唑暴露与先天畸形无显著关联(OR 0.96,95%CI 0.75–1.22;OR 1.08,95%CI 0.90–1.29)。
  • 1项队列研究:甲硝唑暴露儿童癌症发生率未见显著升高(校正相对危险度0.81,95%CI 0.41–1.59)。

临床怎么用

  • 一般产科人群不应期待治疗无症状细菌性阴道病可降低早产风险。
  • 对既往早产史女性,现有证据不足以支持常规筛查治疗以预防早产。
  • 筛查试验选择需考虑灵敏度与特异度差异较大的问题。

局限性

  • 无研究直接评估筛查的获益或危害。
  • 宫内暴露相关研究存在重要局限性,危害证据不充分。
  • 既往早产史女性证据不一致,结论不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preterm delivery results in adverse outcomes; identifying and treating bacterial vaginosis may reduce its occurrence. OBJECTIVE: To update the evidence on screening and treatment of asymptomatic bacterial vaginosis in pregnancy for the US Preventive Services Task Force. DATA SOURCES: MEDLINE, Cochrane Library, and trial registries through May 29, 2019; bibliographies from retrieved articles, experts, and surveillance of the literature through December 31, 2019. STUDY SELECTION: Fair- or good-quality English-language studies evaluating diagnostic accuracy of tests feasible within primary care; randomized clinical trials (RCTs); nonrandomized controlled intervention studies (for harms only); or meta-analyses of metronidazole or clindamycin. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently assessed titles/abstracts and full-text articles, extracted data, and assessed study quality; when at least 3 similar studies were available, meta-analyses were conducted. MAIN OUTCOMES AND MEASURES: Sensitivity, specificity, preterm delivery, maternal adverse effects, congenital birth defects, childhood cancer. RESULTS: Forty-four studies (48 publications) were included. No studies evaluated the benefits or harms of screening. Twenty-five studies (n = 15 785) evaluated the accuracy of screening tests; across individual studies and tests, sensitivity ranged from 0.36 to 1.0 and specificity ranged from 0.49 to 1.0. Among trials reporting findings from general obstetric populations (n = 7953), no significant association was observed between treatment and spontaneous delivery before 37 weeks (pooled absolute risk difference [ARD], -1.44% [95% CI, -3.31% to 0.43%]; 8 RCTs, n = 7571) or any delivery before 37 weeks (pooled ARD, 0.20% [95% CI, -1.13% to 1.53%]; 6 RCTs, n = 6307). Among 5 trials reporting findings among women with a prior preterm delivery, findings were inconsistent; 3 showed a significant beneficial effect, while 2 did not. Maternal adverse events from treatment were infrequent and minor (eg, candidiasis) but were slightly more common with active treatment compared with placebo across 8 RCTs. Two meta-analyses of observational studies reported no significant association between metronidazole exposure and congenital malformations (odds ratio, 0.96 [95% CI, 0.75 to 1.22]; odds ratio, 1.08 [95% CI, 0.90 to 1.29]). One cohort study reported no significantly increased incidence of childhood cancer among metronidazole-exposed children (adjusted relative risk, 0.81 [95% CI, 0.41 to 1.59]). However, studies of in utero exposure had important limitations. CONCLUSIONS AND RELEVANCE: Accuracy of screening tests for bacterial vaginosis varies. The evidence suggests no difference in the incidence of preterm delivery and related outcomes from treatment for asymptomatic bacterial vaginosis in a general obstetric population but was inconclusive for women with a prior preterm delivery. Maternal adverse events from treatment appear to be infrequent and minor, but the evidence about harms from in utero exposure was inconclusive.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kahwati LC, Clark R, Berkman N, et al. Screening for Bacterial Vaginosis in Pregnant Adolescents and Women to Prevent Preterm Delivery: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020. PMID: 32259235. doi:10.1001/jama.2020.0233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。